Biotech's big third quarter is drawing to a close
(JENNIFER KEEFE/STAT)
TG Therapeutics issued what you might describe as a quizzical update to its ongoing cancer trial yesterday, which was reason to update our emoji-fluent biotech scorecard with an appropriately quizzical figure.
And speaking of that scorecard, it is very nearly full after a quarter of news, surprising and otherwise, that shifted billions of dollars in market value. Here's what's left for September:
And speaking of that scorecard, it is very nearly full after a quarter of news, surprising and otherwise, that shifted billions of dollars in market value. Here's what's left for September:
- Esperion Therapeutics is going to learn whether its ambitious plan to disrupt the market for cholesterol drugs has legs when a Phase 3 trial reads out this month.
- Insmed is going to find out what the FDA thinks of its inhalable treatment for a lung infection by Sept. 28, when the agency will decide whether to approve the drug.
- And Regeneron Pharmaceuticals has a shot at winning an early FDA approval for its immuno-oncology drug, giving it a shot to compete in a crowded market ruled by Merck and Bristol-Myers Squibb.
No hay comentarios:
Publicar un comentario